Recently, the nine-valent human papillomavirus (HPV) vaccine, jointly developed by Xiamen University and Xiamen Innovax over 18 years, has received market approval. This marks China's first domestically produced nine-valent HPV vaccine and the world's second. For two decades, Xiamen has prioritized the biopharmaceutical industry, evolving its support framework from basic "factor guarantees" like land provision and tax incentives to establishing a multi-tiered provincial-municipal-district "parallel acceleration" service mechanism, significantly shortening innovation commercialization cycles. After 20+ years of dedicated cultivation, Xiamen now hosts over 1,600 biopharmaceutical and health enterprises, achieving prolific R&D outcomes with an average annual output growth of 20%. The Xiamen Biopharmaceutical Port in Haicang, ranked 13th nationally in competitiveness, has emerged as a pivotal force in China's biopharmaceutical landscape.
